Protein scaffold and expression level determine antiviral activity of membrane-anchored antiviral peptides

Human Gene Therapy

Volumn 20, Issue 4, 2009, Pages 325-336

  Hermann, Felix G ^a   Martinius, Holger ^a   Egelhofer, Marc ^a   Giroglou, Tsanan ^a   Tonn, Torsten ^b   Roth, Stefanie D ^b   Zahn, Roland ^a   Schult Dietrich, Patricia ^a   Alexandrov, Alexander ^c   Dietrich, Ursula ^a   Baum, Christopher ^d,e   Von Laer, Dorothee ^a,f  

^a Georg Speyer Haus   (Germany)

^b Institute for Transfusion Medicine and Immunohematology   (Germany)

^c Fresenius Biotech   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^f INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN G2; LENTIVIRUS VECTOR; MEMBRANE ANCHORED GLYCOPROTEIN GP 41; METHIONYLGLYCYLALANYLGLYCYLALANYLTHREONYLGLYCYLARGINYLALANYLMETHIONYLASPARTYLGLYCYLPROLYLARGINYLLEUCYLLEUCYLLEUCYLLEUCYLLEUCYLLEUCYLLEUCYLGLYCYLASPARAGINYLSERYLLEUCYLGLYCYLGLYCYLALANYLARGINYLSERINE; NERVE GROWTH FACTOR RECEPTOR; OLIGONUCLEOTIDE; RETROVIRUS VECTOR; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG; VALYLPROLYLARGINYLASPARTYLCYSTEINYLGLYCYLCYSTEINYLLYSYLPROLYLCYSTEINYLISOLEUCYLCYSTEINYLTHREONINE;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIGEN BINDING; ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; FLOW CYTOMETRY; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; POLYMORPHONUCLEAR CELL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TRANSGENE; VIRUS ENTRY; VIRUS INHIBITION; VIRUS RESISTANCE; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; C-PEPTIDE; CELL LINE; CELL MEMBRANE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENETIC VECTORS; HIV INFECTIONS; HUMANS; MOLECULAR SEQUENCE DATA; PROTEINS; RETROVIRIDAE; TRANSGENES; VIRUS INTERNALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 64049093511     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.158     Document Type: Article

References (45)

1. Anderson, J., Banerjea, A., and Akkina, R. (2003). Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance. Oligonucleotides 13, 303-312.
2. Artelt, P., Grannemann, R., Stocking, C., Friel, J., Bartsch, J., and Hauser, H. (1991). The prokaryotic neomycin-resistanceencoding gene acts as a transcriptional silencer in eukaryotic cells. Gene 99, 249-254.
3. Bays, N.W., Gardner, R.G., Seelig, L.P., Joazeiro, C.A., and Hampton, R.Y. (2001). Hrd1p/Der3p is a membrane-anchored ubiquitin ligase required for ER-associated degradation. Nat.Cell Biol. 3, 24-29.
4. Becker, S., Simpson, J.C., Pepperkok, R., Heinz, S., Herder, C., Grez, M., Seifried, E., and Tonn, T. (2004). Confocal microscopy analysis of native, full length and B-domain deleted coagulation factor VIII trafficking in mammalian cells. Thromb.Haemost. 92, 23-35.
5. Bertolotti, A., Zhang, Y., Hendershot, L.M., Harding, H.P., and Ron, D. (2000). Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat. Cell Biol. 2, 326-332.
6. Boden, D., Pusch, O., Silbermann, R., Lee, F., Tucker, L., and Ramratnam, B. (2004). Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucleic Acids Res. 32, 1154-1158.
7. Byun, J., Kim, J.M., Robbins, P.D., and Kim, S. (1998). The selectable marker neo gene down-regulates gene expression from retroviral vectors containing an internal ribosome entry site. Gene Ther. 5, 1441-1444.
8. Chan, D.C., Chutkowski, C.T., and Kim, P.S. (1998). Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. U.S.A. 95, 15613-15617.
9. Clapham, P.R., McKnight, A., and Weiss, R.A. (1992). Human immunodeficiency virus type 2 infection and fusion of CD4- negative human cell lines: Induction and enhancement by soluble CD4. J. Virol. 66, 3531-3537.
10. Eckert, D.M., and Kim, P.S. (2001). Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc. Natl. Acad. Sci. U.S.A. 98, 11187-11192.
11. Egelhofer, M., Brandenburg, G., Martinius, H., Schult-Dietrich, P., Melikyan, G., Kunert, R., Baum, C., Choi, I., Alexandrov, A., and von Laer, D. (2004). Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J. Virol. 78, 568-575.
12. Ellgaard, L., and Helenius, A. (2003). Quality control in the endoplasmic reticulum. Nat. Rev. Mol. Cell. Biol. 4, 181-191.
13. Fehse, B., Richters, A., Putimtseva-Scharf, K., Klump, H., Li, Z., Ostertag, W., Zander, A.R., and Baum, C. (2000). CD34 splice variant: An attractive marker for selection of gene-modified cells. Mol. Ther. 1, 448-456.
14. Fehse, B., Kustikova, O.S., Bubenheim, M., and Baum, C. (2004). Pois(s)on: It's a question of dose. Gene Ther. 11, 879-881.
15. Gallo, S.A., Finnegan, C.M., Viard, M., Raviv, Y., Dimitrov, A., Rawat, S.S., Puri, A., Durell, S., and Blumenthal, R. (2003). The HIV Env-mediated fusion reaction. Biochim. Biophys. Acta 1614, 36-50.
16. Greenberg, M.L., Davison, D., Jin, L., Mosier, S., Melby, T., Sista, P., Demasi, R., Miralles, D., Cammack, N., and Matthews, T.J. (2002). In vitro antiviral activity of T-1249. Antiviral Ther. 7, S10.
17. Grignani, F., Kinsella, T., Mencarelli, A., Valtieri, M., Riganelli, D., Lanfrancone, L., Peschle, C., Nolan, G.P., and Pelicci, P.G. (1998). High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV=retroviral vector expressing the green fluorescence protein. Cancer Res.58, 14-19.
18. Hampton, R.Y., Gardner, R.G., and Rine, J. (1996). Role of 26S proteasome and HRD genes in the degradation of 3- hydroxy-3-methylglutaryl-CoA reductase, an integral endoplasmic reticulum membrane protein. Mol. Biol. Cell 7, 2029-2044.
19. Hildinger, M., Abel, K.L., Ostertag, W., and Baum, C. (1999). Design of 50 untranslated sequences in retroviral vectors developed for medical use. J. Virol. 73, 4083-4089.
20. Hildinger, M., Dittmar, M.T., Schult-Dietrich, P., Fehse, B., Schnierle, B.S., Thaler, S., Stiegler, G., Welker, R., and von Laer, D. (2001). Membrane-anchored peptide inhibits human immunodeficiency virus entry. J. Virol. 75, 3038-3042.
21. Jacque, J.M., Triques, K., and Stevenson, M. (2002). Modulation of HIV-1 replication by RNA interference. Nature 418, 435-438.
22. Jiang, S., Lin, K., Strick, N., and Neurath, A.R. (1993). HIV-1 inhibition by a peptide. Nature 365, 113.
23. Johnson, A.E., and van Waes, M.A. (1999). The translocon: A dynamic gateway at the ER membrane. Annu Rev. Cell Dev. Biol. 15, 799-842.
24. Kliger, Y., Gallo, S.A., Peisajovich, S.G., Munoz-Barroso, I., Avkin, S., Blumenthal, R., and Shai, Y. (2001). Mode of action of an antiviral peptide from HIV-1: Inhibition at a post-lipid mixing stage. J. Biol. Chem. 276, 1391-1397.
25. Kondo, E., Akatsuka, Y., Nawa, A., Kuzushima, K., Tsujimura, K., Tanimoto, M., Kodera, Y., Morishima, Y., Kuzuya, K., and Takahashi, T. (2005). Retroviral vector backbone immunogenicity: Identification of cytotoxic T-cell epitopes in retroviral vector-packaging sequences. Gene Ther. 12, 252-258.
26. Lee, B., Sharron, M., Montaner, L.J., Weissman, D., and Doms, R.W. (1999). Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc. Natl. Acad. Sci. U.S.A. 96, 5215-5220.
27. Li, Z., Dullmann, J., Schiedlmeier, B., Schmidt, M., von Kalle, C., Meyer, J., Forster, M., Stocking, C., Wahlers, A., Frank, O., Ostertag, W., Kuhlcke, K., Eckert, H.G., Fehse, B., and Baum, C. (2002). Murine leukemia induced by retroviral gene marking. Science 296, 497.
28. Lohrengel, S., Hermann, F., Hagmann, I., Oberwinkler, H., Scrivano, L., Hoffmann, C., von Laer, D., and Dittmar, M.T. (2005). Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides. J. Virol. 79, 10237-10246.
29. + T-cell clone (PM-1): Failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J. Virol. 69, 3712-3720.
30. Martinez, M.A., Gutierrez, A., Armand-Ugon, M., Blanco, J., Parera, M., Gomez, J., Clotet, B., and Este, J.A. (2002). Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS 16, 2385-2390.
31. Melikyan, G.B., Egelhofer, M., and von Laer, D. (2006). Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion. J. Virol. 80, 3249-3258.
32. Meusser, B., Hirsch, C., Jarosch, E., and Sommer, T. (2005). ERAD: The long road to destruction. Nat. Cell Biol. 7, 766-772.
33. Muster, T., Steindl, F., Purtscher, M., Trkola, A., Klima, A., Himmler, G., Ruker, F., and Katinger, H. (1993). A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67, 6642-6647.
34. Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F.H., Verma, I.M., and Trono, D. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263-267.
35. Novina, C.D., Murray, M.F., Dykxhoorn, D.M., Beresford, P.J., Riess, J., Lee, S.K., Collman, R.G., Lieberman, J., Shankar, P., and Sharp, P.A. (2002). siRNA-directed inhibition of HIV-1 infection. Nat. Med. 8, 681-686.
36. Ofek, G., Tang, M., Sambor, A., Katinger, H., Mascola, J.R., Wyatt, R., and Kwong, P.D. (2004). Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78, 10724-10737.
37. Parodi, A.J. (2000). Role of N-oligosaccharide endoplasmic reticulum processing reactions in glycoprotein folding and degradation. Biochem J. 348, 1-13.
38. Peisajovich, S.G., Gallo, S.A., Blumenthal, R., and Shai, Y. (2003). C-terminal octylation rescues an inactive T20 mutant: Implications for the mechanism of HIV=simian immunodeficiency virus-induced membrane fusion. J. Biol. Chem. 278, 21012-21017.
39. Schambach, A., Wodrich, H., Hildinger, M., Bohne, J., Krausslich, H.G., and Baum, C. (2000). Context dependence of different modules for posttranscriptional enhancement of gene expression from retroviral vectors. Mol. Ther. 2, 435-445.
40. Schambach, A., Schiedlmeier, B., Kuhlcke, K., Verstegen, M., Margison, G.P., Li, Z., Kamino, K., Bohne, J., Alexandrov, A., Hermann, F.G., von Laer, D., and Baum, C. (2006). Towards hematopoietic stem cell-mediated protection against infection with human immunodeficiency virus. Gene Ther. 13, 1037-1047.
41. Schroder, M., and Kaufman, R.J. (2005). ER stress and the unfolded protein response. Mutat. Res. 569, 29-63.
42. Schubert, U., Anton, L.C., Gibbs, J., Norbury, C.C., Yewdell, J.W., and Bennink, J.R. (2000). Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404, 770-774.
43. van Lunzen, J., Glaunsinger, T., Stahmer, I., von Baehr, V., Baum, C., Schilz, A., Kuehlcke, K., Naundorf, S., Martinius, H., Hermann, F., Giroglou, T., Newrzela, S., Müller, I., Brauer, F., Brandenburg, G., Alexandrov, A., and von Laer, D. (2007). Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol. Ther. 15, 1024-1033.
44. von Laer, D., Hasselmann, S., and Hasselmann, K. (2006). Impact of gene-modified T cells on HIV infection dynamics. J. Theor. Biol. 238, 60-77.
45. Ye, Y., Meyer, H.H., and Rapoport, T.A. (2001). The AAA ATPase Cdc48/p97 and its partners transport proteins from the ER into the cytosol. Nature 414, 652-656.